Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

Assumptions of Survival Analysis

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Characterization of the Partition Rate of 2-Naphthol (NAP) and Ritonavir (RTV) Across the Water-Octanol Interface and the Influence of Common Pharmaceutical Excipients.

Journal of pharmaceutical sciences·2020

Same author

Coronavirus disease 2019 in children: Characteristics, antimicrobial treatment, and outcomes.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2020

Same author

Simultaneous Full-Color Printing and Holography Enabled by Centimeter-Scale Plasmonic Metasurfaces.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2020

Same author

Surfactant-laden bubble dynamics under porous polymer films.

Journal of colloid and interface science·2020

Same author

Long Noncoding RNA DLX6-AS1 Regulates the Growth and Aggressiveness of Colorectal Cancer Cells Via Mediating the miR-26a/EZH2 Axis.

Cancer biotherapy & radiopharmaceuticals·2020

Same author

Succinate induces skeletal muscle fiber remodeling via SUCNR1 signaling.

EMBO reports·2020

Search research articles

Related Experiment Video

Updated: Jun 27, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Adaptive two-stage seamless sequential design for clinical trials.

Ping Gao¹, Yingqiu Li²

¹Biostatistics, Innovatio Statistics, Inc ., Bridgewater, USA.

Journal of Biopharmaceutical Statistics

|May 5, 2024

Summary

This summary is machine-generated.

This study introduces a flexible adaptive sequential testing method for clinical trials, allowing for adaptive treatment selection and sample size adjustments. This approach enhances efficiency in multi-option drug development and testing.

Keywords:

Brownian motion approximation adaptive two stage sequential design seamless combination treatment selection

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Related Experiment Videos

Last Updated: Jun 27, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Area of Science:

Biostatistics
Clinical Trial Design
Pharmaceutical Research

Background:

Traditional clinical trial designs often lack flexibility in selecting and testing multiple treatment options.
Pre-specified selection rules can limit the ability to adapt to emerging efficacy and safety data.

Purpose of the Study:

To propose an adaptive sequential testing procedure for combined phase II/III trials.
To enable flexible selection of treatment options based on evolving data, not limited to 'best' selection.
To provide accurate sample size and power calculations for this adaptive design.

Main Methods:

An adaptive sequential testing procedure is developed for selecting and testing multiple treatment options.
The procedure allows for flexible, non-pre-specified selection rules at the end of phase 2.
Statistical methods for sample size, power, and inference (p-value, confidence intervals) are provided and validated by simulation.

Main Results:

Sample size and power calculations are confirmed accurate through simulations.
The procedure accommodates interim analyses and sample size modifications post-selection.
The method is applicable to various endpoint distributions, including normal, binary, Poisson, negative binomial, and time-to-event data, and mixtures thereof.

Conclusions:

The proposed adaptive sequential testing procedure offers a flexible and efficient approach for clinical trials with multiple treatment options.
This method allows investigators to adapt trial conduct based on efficacy and safety data, improving decision-making.
The procedure's broad applicability across different endpoint types supports its utility in diverse pharmaceutical research settings.